Gujarat Themis Biosyn raises $79M via QIP at Rs 354 a share
What's the deal? Gujarat Themis BiosynDealroom has a profile for this one. Try Dealroom → has raised about $78.6 million (Rs 7.5 billion) through a Qualified Institutional Placement (QIP), issuing 21,186,440 new equity shares at Rs 354 each. Its fund-raising committee closed the issue on August 28, 2026, after the process opened on August 25.
The terms: The price marks a 4.98% discount to the floor price of Rs 372.57. The shares were allotted to qualified institutional buyers.
What's the endgame? The company said the proceeds will fund business objectives and growth plans set out in its placement document. Specific capital-expenditure projects have not yet been disclosed.
What could go wrong? Issuing more than 21 million new shares dilutes existing equity, which can weigh on earnings per share. Investors will watch how efficiently the company deploys the fresh capital.
The signal: The round sits toward the smaller end of deals in the sector, but it points to a widening path for listed Indian biotech firms tapping institutional capital directly rather than returning to primary markets.
Read more: whalesbook.com
Image credit: Generated with Gemini
